Heart failure with preserved ejection fraction represents a major diagnostic and therapeutic hurdle across cardiology and internal medicine. Cardiometabolic comorbidities such as type 2 diabetes and hypertension frequently trigger pathological left ventricular remodeling. Consequently, clinicians encounter patients suffering from severe exercise intolerance and elevated filling pressures despite normal systolic ejection. Emerging research highlights that intrinsic cardiomyocyte diastolic stiffness serves as a primary cellular driver of this diastolic dysfunction. Understanding the precise molecular and mechanical determinants behind elevated resting myocardial tension is therefore critical for designing targeted pharmacotherapies. A groundbreaking pre-clinical investigation offers profound insights into how sarcomeric tension, cytoskeletal microtubule networks, and persistent crossbridge activation interact to compromise cardiac relaxation across biological sexes.

Pathophysiological Determinants of Cardiomyocyte Diastolic Stiffness

At the cellular level, resting myocardial compliance depends on three primary biophysical elements. First, passive sarcomere stress largely arises from titin, the giant molecular spring spanning the sarcomere from the Z-disc to the M-line. Post-translational modifications, such as altered phosphorylation or isoform switching, can substantially elevate titin-mediated tension. Second, the intracellular microtubule network forms a dense cytoskeletal scaffold that resists rapid mechanical deformation during early diastole. Post-translational detyrosination of tubulin further augments this viscoelastic resistance, impairing rapid ventricular filling. Third, residual diastolic crossbridges, which fail to detach following systolic contraction, generate persistent active isometric force during relaxation.

Historically, cardiovascular researchers struggled to isolate the relative contributions of these three components under complex cardiometabolic stress. In healthy myocardium, crossbridges rapidly disengage during diastole, allowing the sarcomere to lengthen smoothly. However, systemic metabolic inflammation, oxidative stress, and impaired cyclic guanosine monophosphate signaling perturb these delicate homeostatic pathways. Consequently, cardiomyocyte resting tension rises dramatically, precipitating elevated left ventricular end-diastolic pressures. Deciphering how these individual structural and contractile contributors behave in heart failure with preserved ejection fraction remains essential for tailoring patient-specific molecular therapies.

Experimental Modeling of Cardiometabolic HFpEF Phenotypes

To systematically delineate these mechanics, investigators utilized a robust two-hit murine model that faithfully recapitulates human cardiometabolic disease. By combining high-fat diet feeding with systemic nitric oxide synthase inhibition, the researchers induced concurrent obesity, glucose intolerance, and systemic hypertension. Subsequently, intact single cardiomyocytes were isolated from both male and female animals to evaluate cellular mechanics under physiological pacing and temperature.

The experimental design employed a high-precision stretch-release protocol to establish the diastolic stress-sarcomere length relationship across viable cardiomyocytes. To dissect specific mechanical determinants, researchers applied targeted pharmacological inhibitors sequentially. Specifically, 2,3-butanedione monoxime served to inhibit active crossbridge cycling, while colchicine treatment effectively depolymerized the intracellular microtubule lattice. Furthermore, investigators measured true passive sarcomeric tension by combining both agents to abolish active cycling and microtubule stiffness simultaneously. This rigorous methodology allowed unambiguous quantification of each cellular component. By analyzing both sexes under identical experimental protocols, the study unveiled striking sex-dependent biomechanical divergence that challenges the traditional one-size-fits-all paradigm of heart failure management.

Sex-Specific Divergence in Sarcomere Stress and Diastolic Crossbridges

The investigation revealed unexpected and clinically profound sex differences in the mechanical profiles of failing cardiomyocytes. In male HFpEF-like cardiomyocytes, overall resting diastolic tension increased dramatically due to a dual pathological mechanism. Specifically, male cells demonstrated a 70% increase in passive sarcomere stress alongside a remarkable 52% elevation in diastolic crossbridge activity. In contrast, female HFpEF-like cardiomyocytes exhibited an isolated 55% increase in passive sarcomere stiffness without any significant elevation in diastolic crossbridge engagement.

This fundamental divergence indicates that male and female hearts arrive at diastolic dysfunction through distinct cellular and biophysical pathways. In females, pathological stiffening reflects passive structural alterations within the sarcomere, predominantly localized to the titin spring complex and myofilament architecture. Conversely, males experience a compounded burden of passive stiffness and active incomplete crossbridge detachment. Thus, male cardiomyocytes remain partly engaged in low-level contractile tension throughout the entire diastolic interval. Consequently, these findings emphasize that therapeutic strategies targeting active crossbridge kinetics may yield substantial functional benefits in males, whereas passive structural modifications require distinct interventions in females.

Cytoskeletal Microtubules and Dysregulated Calcium Dynamics

The research also illuminated the complex interplay between cytoskeletal architecture and active contractile elements. In male HFpEF-like cardiomyocytes, the dense microtubule network contributed significantly to overall diastolic stress by augmenting the formation of persistent diastolic crossbridges. When colchicine depolymerized microtubules, it substantially decreased crossbridge-dependent tension in males, highlighting a previously unrecognized cooperative interaction between the tubulin cytoskeleton and crossbridge cycling kinetics.

Furthermore, dynamic imaging demonstrated that elevated diastolic crossbridge activity in males coincided with altered intracellular calcium transients. Impaired sarcoplasmic reticulum calcium reuptake via SERCA2a and elevated resting cytosolic calcium concentrations prevent complete myofilament relaxation. Because elevated diastolic calcium maintains troponin in a partially active conformation, myosin heads continue to interact with actin filaments during resting phases. Therefore, altered calcium handling directly fuels the persistent crossbridge cycling observed in male myocytes. In females, preserved calcium transients appear to protect against pathological crossbridge retention, confining diastolic stiffness to passive titin-based compliance changes. These mechanistic insights clearly link cytoskeletal stress, calcium dysregulation, and mechanical stiffness.

Translational Implications for Targeted HFpEF Therapies

These discoveries have significant clinical implications for the precision management of patients with cardiometabolic heart failure. Currently, clinicians rely primarily on sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, and lifestyle modifications to manage systemic fluid retention and metabolic disease. However, these therapies do not specifically address distinct intracellular stiffening mechanisms.

Because male cardiometabolic HFpEF involves prominent crossbridge persistence and calcium mishandling, novel small-molecule myosin modulators and therapies enhancing calcium clearance may prove exceptionally valuable for male patients. For instance, direct sarcomere modulators or agents improving SERCA2a activity could selectively alleviate male diastolic tension. Conversely, for female patients, therapeutic innovation must prioritize restoring titin compliance, potentially through cyclic GMP-protein kinase G signaling activators or anti-fibrotic pathways that remodel passive cytoskeletal elements. Tailoring pharmacological approaches to these sex-specific mechanical drivers will undoubtedly accelerate the evolution of personalized heart failure therapy.

Frequently Asked Questions

What are the primary cellular determinants of cardiomyocyte diastolic stiffness?

Cardiomyocyte diastolic stiffness is primarily determined by three distinct cellular mechanisms: passive sarcomere elasticity governed by the giant spring protein titin, viscoelastic resistance provided by the cytoskeletal microtubule network, and isometric tension generated by residual diastolic crossbridges. Under cardiometabolic stress, pathological modifications in titin phosphorylation, microtubule detyrosination, and incomplete crossbridge detachment significantly increase resting myocardial tension and filling pressures.

How do male and female cardiomyocytes differ in HFpEF diastolic mechanics?

Male and female cardiomyocytes exhibit distinct biomechanical mechanisms in cardiometabolic HFpEF. Male cardiomyocytes display a compounded stiffness profile characterized by a 70% increase in passive sarcomere stress and a 52% elevation in diastolic crossbridge activity. In contrast, female cardiomyocytes exhibit an isolated 55% increase in passive sarcomere stress without significant crossbridge elevation, highlighting key sex-specific therapeutic targets.

Why does calcium handling dysregulation increase diastolic stiffness in males?

Altered intracellular calcium handling directly elevates diastolic stiffness by impairing complete cardiomyocyte relaxation. In male cardiometabolic HFpEF, elevated resting diastolic calcium levels and slowed calcium transient decay maintain troponin complexes in an active state. This persistent calcium availability promotes continuous actin-myosin crossbridge interactions throughout diastole, generating persistent active tension that resists passive ventricular filling.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is intended for healthcare professionals. Clinical decisions must be based on individual patient assessments and established medical guidelines. Refer to the latest local and national guidelines for clinical practice.

References

1. Shahid A et al. Diastolic contributors in cardiomyocytes of a cardiometabolic HFpEF-like mouse model. J Gen Physiol. 2026 Nov 02. doi: undefined. PMID: 42640268.
2. Caporizzo MA, Chen CY, Bedi K, Margulies KB, Prosser BL. Microtubules increase diastolic stiffness in failing human cardiomyocytes and myocardium. Circulation. 2020;141(11):902-915.
3. Chung CS, Granzier HL. Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. J Mol Cell Cardiol. 2011;50(6):967-974.